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RESEARCH ARTICLE
Atopy and Inhaled Corticosteroid Use
Associate with Fewer IL-17+ Cells in
Asthmatic Airways
Fatemeh Fattahi1,2,3,4, Corry-Anke Brandsma2,3, Monique Lodewijk2,3, Marjan Reinders-
Luinge2,3, Dirkje S. Postma1,3, Wim Timens2,3, Machteld N. Hylkema2,3, Nick H. T. ten
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Groningen, Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands, 4 Immunology,




Interleukin (IL)-17 plays a critical role in numerous immune and inflammatory responses
and was recently suggested to contribute to the pathogenesis of nonatopic (non-eosinophil/
neutrophil-dominant) asthma. We aimed to compare expression of IL-17 in bronchial air-
ways between atopic and nonatopic asthmatics, with/without inhaled corticosteroid (ICS)
use and to identify its major cellular source.
Methods
Bronchial biopsies from 114 patients with mild-to-moderate asthma were investigated: 33
nonatopic, 63 non-corticosteroid users, 90 nonsmokers. IL-17 expression was correlated
with atopy and inflammatory cell counts (EPX, NP57, CD3, CD4, CD8, CD20, CD68), taking
ICS use and smoking into account. Multiple linear regression analyses were used to deter-
mine the independent factors as well as the most relevant inflammatory cells contributing to
IL-17 expression. Double immunostainings were performed to confirm the major cellular
source of IL-17.
Results
In non-ICS users, nonatopic asthmatics had more IL-17+ cells in the airway wall than atopic
asthmatics. In both atopic and nonatopic asthmatics, ICS use was associated with lower
numbers of IL-17+ cells, independent of smoking. The number of IL-17+ cells was associ-
ated with the number of neutrophils (B: 0.26, 95% CI: 0.17–0.35) and eosinophils (B: 0.18,
95% CI: 0.07–0.29). The majority of IL-17+ cells were neutrophils, as confirmed by double
immunostaining.
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Conclusions
We show for the first time that atopy and ICS use are associated with lower numbers of IL-
17+ cells in asthmatic airways. Importantly, IL-17+ cells were mostly neutrophils which con-
flicts with the paradigm that lymphocytes (Th17) are the main source of IL-17.
Introduction
Asthma is a chronic inflammatory disease of the airways, characterized by reversible
airway obstruction and bronchial hyperresponsiveness (BHR) [1]. One of the oldest ways
to discern asthmatic patients is based on the presence or absence of atopy [2]. Not surpris-
ingly, the underlying airway pathology of atopic versus nonatopic asthma is different,
showing high numbers of eosinophils, T lymphocytes and Th2 cytokines (interleukin (IL)-
4 and IL-5) in atopic asthma versus high numbers of neutrophils and non-Th2 cytokines
(IL-8) in nonatopic asthma [3]. One of the cytokines that was recently suggested to contrib-
ute to the pathogenesis of nonatopic (non-eosinophil/neutrophil-dominant) asthma is
IL-17 [4].
IL-17, also called IL-17A, is a proinflammatory cytokine, implicated in the development of
autoimmunity, tumorigenesis and host defenses against bacterial and fungal infections [5]. In
the lung, increased levels of IL-17 have been demonstrated in inflammatory disorders like
asthma and chronic obstructive pulmonary disease (COPD) [6–10]. IL-17 was first shown to
be produced by activated CD4+ memory T cells [11]. Thereafter, a specific subset of Th cells,
namely the Th17 cells, has been put forward as its main producer [12, 13]. Th17 cells have
been shown to mediate airway inflammation and hyperresponsiveness associated with non-
eosinophilic asthma in mice, and importantly do not respond well to glucocorticoid treatment
[14]. In humans, Th17 cells have also been suggested to play a role in regulating a neutrophil
and macrophage dominant type of inflammation in the lung, particularly in severe, steroid-
insensitive asthma and COPD [6]. In line with this, IL-17 levels were found to correlate posi-
tively with sputum neutrophilia in severe asthma [7, 15].
On the other hand, IL-17 has also been implicated in Th2 responses. In mouse models of
asthma, Th17 cells were shown to home to the lung and enhance not only neutrophilic airway
inflammation but also Th2 cell-mediated eosinophilic airway inflammation [16]. And in
patients with allergic asthma increased levels of IL-17 were demonstrated after a challenge with
house dust mite [17].
Although there has been substantial interest in elucidating the role of IL-17 in neutro-
phil-dominant/nonatopic asthma in humans [4, 18], our understanding regarding this
phenotype of asthma is still very limited. Although recent studies suggest that a higher level
of IL-17 expression is associated with severe asthma, the atopic status was not included in
their analysis [19–22]. In fact, there is no data comparing IL-17 expression between atopic
and nonatopic asthma patients. We therefore investigated the expression of IL-17 in bron-
chial biopsies from a large cohort of well characterized atopic and nonatopic asthmatic
patients, also taking into account the effect of inhaled corticosteroid (ICS) and smoking.
Additionally, we identified the major cellular source of IL-17 in the airway walls of these
asthma patients.
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rs, Spearman rank-order coefficient; FEV1, Forced
expiratory volume in one second; VC, Vital capacity;
MEF50, Maximum expiratory flow rate at 50% of vital
capacity; AMP PC20, Provocative concentration of
adenosine 5'- monophosphate causing a 20% fall in
FEV1; NO, Nitric oxide.
Materials and Methods
Subjects
We investigated 114 stable, mild-to-moderate subjects with current asthma from our large
asthma cohorts that were recruited previously by our research group in the University Medical
Center Groningen [23]. Atopic and nonatopic patients, with or without ICS use, aged between
19–71 years were included (Table 1). All patients had a doctor’s diagnosis of asthma and dem-
onstrated reversibility and BHR to histamine and/or adenosine 5’-monophosphate (AMP)
[23]. All patients also had alveolar and bronchial exhaled nitric oxide (NO) values on the Aero-
crine NO system (Niox; Aerocrine AB, Stockholm, Sweden) measured in accordance with
international guidelines as described in an earlier study [23]. Atopic status was determined by
Phadiatop for all 114 patients using the ImmunoCap system (Phadia AB, Uppsala, Sweden),
and expressed as ratios (fluorescence of the serum of interest divided by the fluorescence of a
control serum). A positive Phadiatop was defined as patient serum/control serum>1. The
Medical Ethics Committee of the University Medical Center Groningen approved the study
protocol and all subjects gave written informed consent.
Immunohistochemical staining and cellular quantification of bronchial
biopsies
Paraffin embedded bronchial biopsies were cut into 3-μm-thick sections. Sections were depar-
affinized and, after antigen retrieval, incubated with appropriate polyclonal antibodies against
Table 1. Patient characteristics.
ICS user Non-ICS user
Atopic (n = 39) Nonatopic (n = 12) Atopic (n = 42) Nonatopic (n = 21)
Sex, males/females 19/20 6/6 26/16 10/11
Age, Years 50 (22–68) 50 (30–71) 48 (22–70) 50 (21–65)
BMI, Kg/m2 25.6 (19–39) 26.3 (19.5–44.2) 27.2 (19.3–40.4) 27.2 (21.4–42.4)
Smoking, yes/no 6/33 1/11 12/30 5/16
Age of asthma onset 8 (1–55) 21 (1–40) 7 (1–48) 14.5 (3–22)
Asthma duration 44 (3–58) 22 (5–44) 42 (4–60) 35.5 (1–57)
ICS dose, μg/day 800 (28–2000) 1000 (400–2000) ____ ____
High doses of ICS (>1000μg/day) 9 (23.1%) 5 (41.7%) ____ ____
FEV1, % pred 95.6 (42.5–121.3) 104.5 (52.1–135.3) 97.9 (59.8–122.0) 105.4 (84.0–122.7)
#
FEV1/VC, % 71.5 (39.9–96.7) 73.3 (39.4–94.1) 71.7 (47.6–97.7) 80.0 (67.0–93.6)*
AMP PC20, mg/ml 51.5 (0.0–640) 640 (0.01–640) 83.9 (0.02–640) 640 (0.08–640)#
Reversibility, % pred 8.7 (-0.8–38.4) 7.3 (0.73–20.0) 9.1 (-0.24–28.7) 6.2 (-1.4–17.4)
Total IgE (IU/ml) 146 (5–1668) 78 (17–359) 94 (9–1302) 36.5 (1–295)*
Speciﬁc IgE (PAU/l) 24.4 (1.7–128) 0.21 (0.15–0.92)* 22.5 (1.2–106) 0.26 (0.06–0.76)*
NO Bronchial (nl/s) 0.89 (0.2–10.4) 0.3 (0.09–2.5)* 0.8 (0.06–3.2) 0.5 (0.09–1.1)
NO Alveolar (ppb) 6.1 (1.5–51.7) 4.3 (1.9–11.9) 5.9 (2.08–18.3) 3.8 (0.9–8.2)*
Deﬁnition of abbreviations: ICS: inhaled corticosteroid (beclomethasone equivalent); FEV1: forced expiratory volume in one second, measured after
inhalation of 800 μg albuterol; VC: vital capacity; MEF50: maximum expiratory ﬂow rate at 50% of vital capacity; AMP PC20: provocative concentration of
adenosine 5'- monophosphate causing a 20% fall in FEV1; All values was obtained 15 min after inhalation of 1 mg terbutaline. Reversibility: change in FEV1,
expressed as increase in percentage predicted normal value after 400 μg of albuterol. Normal reversibility was deﬁned a greater than 12% and 200 ml
increase in FEV1 following inhalation of the bronchodilator (Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2014.
Available from: http://www.ginaasthma.com). PAU/l: Phadia Arbitrary Units per litre; NO: nitric oxide
Values are number (no.) or medians with minimum-maximum ranges in parentheses.
*p<0.05 vs atopic (in ICS or non-ICS user);
#trend: 0.05<p<0.10 vs atopic (in ICS or non-ICS user).
doi:10.1371/journal.pone.0161433.t001
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IL-17 (R&D Systems, polyclonal Goat anti-Human, AF-317-NA), using the DAKO autostainer
in three consecutive runs. The slides were included in random fashion in each run to avoid
group wise staining (19). The number of positive cells was counted by a blinded observer in the
submucosal area 100 μm under the basement membrane in the biopsy sample (19) using Aperio
Image Scope software. The same techniques had been already applied for immunohistochemi-
cal staining and cellular quantification of other inflammatory cells including: neutrophils
(NP57, DAKO, Glostrup, Denmark), eosinophils (eosinophil peroxidase; EPX, laboratories of
NA Lee and JJ Lee, Mayo Clinic, Scottsdale, AZ), macrophages (CD68, DAKO, Glostrup, Den-
mark), mast cells (AA1, DAKO, Glostrup, Denmark) and T-cells (CD3, CD4, CD8, DAKO,
Glostrup, Denmark)[23].
Double immunostainings were performed to elucidate whether granulocytes are a source of
IL-17 in bronchial biopsies of asthmatics. Primary neutrophil and eosinophil antibodies suit-
able for double staining with IL-17 were used; a polyclonal Rabbit anti-Human Myeloperoxi-
dase (MPO) antibody (DAKO, Glostrup, Denmark) was used to identify neutrophils and a
Mouse anti-Human EPX antibody (Mayo Clinic, Scottsdale, AZ, USA) to identify eosinophils.
After deparaffinizing the slides, a heat-induced antigen (epitope) retrieval protocol was used
and blocking for endogenous peroxidase was applied. As secondary antibodies, peroxidase con-
jugated Swine anti-Rabbit IgG Antibody (DAKO, Glostrup, Denmark) was used for detecting
MPO stained cells, biotinylated labeled Rabbit anti-Mouse antibody (DAKO, Glostrup, Den-
mark) for detecting EPX stained cells and Alkaline Phosphatase conjugated Donkey anti-Goat
IgG antibody (SouthernBiotech, USA) for detecting IL-17 stained cells. Double immunostain-
ing with lymphocytes was unnecessary because the vast majority of the IL-17+ cells showed the
morphology of granulocytes. This was confirmed by the MPO/IL17 and EPX/IL17 double
immunostainings.
Statistics
All analyses were performed using SPSS software (version 19.0; SPSS Inc., Chicago, IL). Nor-
mality of distributions was assessed using histograms and/or p-p plots.
For quantitative variables analysis, one-way ANOVA followed by Tukey post-hoc test was
performed for multiple comparisons and t tests or Mann-Whitney U tests was used for two
samples comparison.
Chi-square tests were used to compare groups for dichotomous variables. Correlations were
evaluated by Pearson (for normally distributed data) or Spearman (for non-normally distrib-
uted data) tests. Multiple linear regression analysis was used to assess the independent contri-
bution of ICS use (yes/no), smoking (smoking vs. nonsmoking) and Phadiatop (atopic vs.
nonatopic) to IL-17 expression (dependent variable). To find the most relevant inflammatory
cells contributing to IL-17 expression, additional linear regressions were performed on inflam-
matory markers (neutrophil, eosinophil, T-cell, macrophage, mast cell) as independent vari-
ables (separately for each one or in combination with other inflammatory cells) and IL-17 as
dependent variable, adjusting for atopy, smoking status and ICS use. For all statistical analyses,
p values<0.05 were considered statistically significant.
Results
Inflammatory cells counts in blood, sputum and bronchial biopsies
In the group of asthma patients who did not use ICS, there were trends towards lower blood
eosinophil counts (p = 0.08) and lower percentage of sputum eosinophils (p = 0.06) in nonatopic
asthma patients compared to atopic patients (Table 2). In addition, nonatopic patients had more
neutrophils in the bronchial submucosa than atopic patients, whereas the atopic asthmatics had
Atopy and ICS Effect on IL-17 Expression in Asthma
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more eosinophils (Table 2). In the group of patients who did use ICS, the nonatopic individuals
had more CD8+ cells in the bronchial submucosa than the atopic ones (Table 2).
Lower IL-17 expression in bronchial biopsies associated with atopy and
ICS use
In the group of non-ICS users, there were significantly more IL-17+ cells in the bronchial sub-
mucosa of nonatopic asthmatics compared to atopic ones (Fig 1). In line with this finding, a
negative correlation was found between IL-17+ cells numbers and the Phadiatop score (rs =
-0.37, p<0.001) (Fig 2).
Both atopic and nonatopic asthma patients treated with ICS had lower numbers of IL-17+
cells than those without ICS treatment (Fig 1). There were 9 subjects in the atopic group and 5
subjects in the nonatopic group who used high doses of ICS (>1000ug daily) (Table 1). There
was no association between doses of ICS (high doses vs. mild-moderate doses) and cellular
infiltrate.
There was a significant negative correlation between IL-17+ cells numbers and reversibility
levels in the total population who did not use ICS (both atopic and nonatopic subjects) (rs =
-0.33; p = 0.01) (S1A Fig) in line with a negative correlation between neutrophils levels and
reversibility levels in the total population who used ICS (both atopic and nonatopic subjects)
(rs = -0.27; p = 0.04). There was also a negative correlation between FEV1% predicted and IL-
17 + cells numbers in the atopic individuals who did not use ICS (rs = -0.39; p = 0.01)(S1B Fig).
There was no association between current smoking and IL-17 levels (S2 Fig) and current
smoking had no effect on IL-17 counts in all groups of asthmatics.
Using regression analyses, we demonstrated that the absence of atopy (B: -2.42, 95% CI:
-4.16- -0.69) and non-ICS use (B: -4.29, 95% CI: -5.85- -2.74) most strongly contributed to the
Table 2. Inflammation in atopic and nonatopic asthmatics.
ICS user Non-ICS user
Atopic (n = 39) Nonatopic (n = 12) Atopic (n = 42) Nonatopic (n = 21)
Blood
Eosinophil, ×109/L 0.21 (0.04–0.97) 0.15 (0.07–0.78) 0.18 (0.02–0.5) 0.12 (0.03–0.46)#
Sputum
Total cells, ×106/ml 0.5 (0.1–5.2) 0.5 (0.15–1.8) 0.3 (0.3–2.1) 0.4 (0.1–2.2)
Eosinophil, % 1.2 (0–67.1) 0.37 (0–38.6) 1.02 (0–16.7) 0.2 (0–5.2)#
Neutrophil, % 55.8 (16.8–88.8) 53.4 (43.7–88.6) 59.6 (19.8–93.6) 57 (20.7–94.5)
Bronchial biopsies (/0.1mm2)
Eosinophils (EPX+) 1.1 (0–32.4) 1.8 (0–23.3) 2.6 (0–40.3) 0.3 (0–19.1)*
Neutrophils (NP57+) 4.8 (0–33.8) 6.2 (0.9–16.2) 5.8 (0–38.2) 10.4 (0–46)*
Mast cells (AA1+) 8 (0–22.2) 8.3 (0–16.7) 8.1 (0–26.3) 8.7 (0–24.4)
Macrophages (CD68+) 11.8 (0–37.1) 19.5 (4.3–57) 11.6 (0.31–30.1) 13.2 (0–36.5)
T lymphocytes (CD3+) 65 (4.2–219) 81.1 (29.7–216) 77.3 (12.5–294) 61 (18–136.7)
T lymphocytes (CD4+) 14.3 (0–101.2) 27.4 (4.3–57.6) 22 (0–67.2) 18.5 (0.85–58.2)
T lymphocytes (CD8+) 17.7 (0.98–205.2) 38.3 (0–78.4)* 21.1 (1.02–112.3) 15.9 (3–139)
B lymphocytes (CD20+) 2.9 (0–37.1) 6.05 (0.9–55.5)# 1.9 (0–98.3) 2.6 (0–20.5)
IL-17+ cells 6.2 (1.2–18.4) 8.5 (4.6–16.9) 11.5 (3.9–29.6) 15.3 (9.7–24.9)*
Values are medians with minimum-maximum ranges in parentheses.
*p<0.05 vs atopic (in ICS or non-ICS user);
#trend: 0.05<p<0.10 vs atopic (in ICS or non-ICS user).
doi:10.1371/journal.pone.0161433.t002
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Fig 1. Number of IL-17+ cells in submucosa in bronchial biopsies from atopic and nonatopic
asthmatics who are inhaled corticosteroid (ICS) users or non-ICS users.
doi:10.1371/journal.pone.0161433.g001
Fig 2. Negative correlation between the number of IL-17+ cells in the submucosa of bronchial biopsies and serum
specific IgE (Phadiatop) from asthmatics (rs = -0.37; P<0.001).
doi:10.1371/journal.pone.0161433.g002
Atopy and ICS Effect on IL-17 Expression in Asthma
PLOSONE | DOI:10.1371/journal.pone.0161433 August 23, 2016 6 / 12
number of IL-17+ cells. There was no significant contribution of smoking status (defined as
smoking and nonsmoking) (B: 0.17, 95% CI: -1.78–2.14).
IL-17 expression positively associated with neutrophilic inflammation
The number of IL-17+ cells in airway wall biopsies correlated significantly with the number of
neutrophils, both in atopic (rs = 0.44; p<0.001) and nonatopic asthmatics (rs = 0.45; p = 0.009)
(Fig 3A), and both in ICS users (rs = 0.35; p = 0.01) and non-ICS users ((rs = 0.48; p<0.0001)
(Fig 3B). Additionally, in atopic asthmatics the number of IL-17+ cells correlated significantly
with the number of eosinophils (rs = 0.36; p = 0.001), CD4
+ cells (rs = 0.33; p = 0.003), CD3
+
cells (rs = 0.31; p = 0.005), and CD8
+ cells (rs = 0.27; p = 0.015).
Using regression analysis and after adjusting for atopy, ICS use and smoking, we confirmed
the contribution of neutrophils (B: 0.26, 95% CI: 0.17–0.35) as well as eosinophils, with lower
value (B: 0.18, 95% CI: 0.07–0.29) to the number of IL-17+ cells. Other inflammatory cells did
not contribute significantly to IL-17 expression (data not shown).
We found that the majority (~90%) of IL-17+ cells were granulocytes, mostly neutrophils, as
indicated by double staining for IL-17 and MPO and nuclear morphology (Fig 4). In addition,
we identified a few IL-17+ eosinophils, as indicated by double staining for IL-17 and EPX. Fig 4
shows one representative IHC staining for IL-17 for all 4 studied subgroups (frame A-D) and
double staining of IL-17 and MPO (frame E-G) and staining of IL-17 and EPX (frame H-J)
from an asthmatic patient with high numbers of neutrophils (frame E-G) or eosinophils
(frame H-J).
Discussion
This is the first study comparing cellular IL-17 expression in well characterized atopic and non-
atopic asthma patients. We demonstrate that IL-17 was particularly expressed by neutrophils
in the airway biopsies, contrasting with the paradigm that lymphocytes (Th17) are the main
source of IL-17. Our results show that in patients who do not use ICS, nonatopic asthmatics
have more IL-17 expressing cells in the airway wall than atopic asthmatics. In contrast, ICS use
was associated with lower numbers of IL-17 expressing cells in both atopic and nonatopic
asthmatics.
Fig 3. Positive correlation between the number of IL-17+ cells and neutrophils in the submucosa of bronchial biopsies from atopic
(rs = 0.44; p<0.001) and nonatopic (rs = 0.45, p = 0.009) asthmatics (A), or from asthmatics who are inhaled corticosteroid (ICS) (rs =
0.35; p = 0.01) and non-ICS (rs = 0.48; p<0.0001) users (B).
doi:10.1371/journal.pone.0161433.g003
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A new finding of our study is that IL-17 expressing cells in bronchial biopsies of asthma
patients were predominantly granulocytes and not lymphocytes. We confirmed this by double
immunostaining with IL-17 and MPO and by demonstrating a strong positive correlation
between IL-17 expressing cells and neutrophils. Although, perhaps surprising, neutrophils have
been reported as a source of IL-17 in humans [24, 25] as well as in animal studies [25–29]. In
vitro investigations also showed production of IL-17 by stimulated neutrophils with immune
complex [27]. Eosinophils may be another source of IL-17, as suggested by double immunos-
taining of IL-17 and EPX, and by the significant correlation between IL-17+ cells and eosinophil
numbers in atopic asthma patients. Previous findings in the literature are in line with our find-
ing that IL-17 expressing cells in the airways may be granulocytes. Eustace et al showed that IL-
17 in bronchial biopsies of COPD patients was expressed by neutrophils, next to mast cells, T
cells, and B cells in the subepithelium of the small airways [30]. Molet et al demonstrated in
asthma that eosinophils in sputum, brochoalveolar lavage fluid, and peripheral blood express
IL-17 [10]. Finally, Tan et al demonstrated in children with cystic fibrosis that neutrophils and
γδT cells in the airways produce IL-17, next to Th17 cells [31]. These data together support the
reports showing the early sources of IL-17 are the innate immune cells and they have a central
role in the initiation of IL-17-dependent immune responses, even before the first CD4+ T cell
sees its cognate antigen and initiate the Th17 development program [32].
We found more IL-17 expressing cells in the airway wall of nonatopic than atopic asth-
matics, that is those who did not use ICS. It has been suggested that IL-17 may contribute to
the pathogenesis of neutrophil-dominant/nonatopic rather than to eosinophil-dominant/
atopic asthma [4]. Presence of fewer eosinophils and more neutrophils in our nonatopic asth-
matic subjects and the significant contribution of both cell types to IL-17+ cells in our biopsies
Fig 4. IL-17 expression in the submucosa of bronchial biopsies of 4 groups of studied population. atopic inhaled
corticosteroid (ICS) user (frame A), nonatopic ICS user (frame B), atopic non-ICS user (frame C), nonatopic non-ICS user
(frame D). Single staining for IL-17 (frame E; blue) and MPO (frame F; red) and double staining for IL-17 and MPO (frame
G; purple) in adjacent sections of a nonatopic non-ICS user asthmatic patient. Single staining for IL-17 (frame H; blue) and
EPX (frame I; red) and double staining for IL-17 and EPX (frame J; purple) in adjacent sections of an atopic non-ICS user
asthmatic patient.
doi:10.1371/journal.pone.0161433.g004
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support this hypothesis. Interestingly, we found ICS use to be associated with lower IL-17
expression in bronchial biopsies of both atopic and nonatopic asthmatics. This is in line with a
bronchial biopsy study in 10 patients with moderate-to-severe asthma (all atopic) demonstrat-
ing a significantly reduction in the number of IL-17+ cells in the airways after a 2-week course
of oral corticosteroid treatment [8]. Accordingly, IL-17 levels in sputum of 15 mild-moderate
and 15 severe asthmatics decreased after one month of ICS treatment [15]. In vitro data are
also in line with these findings as corticosteroids could inhibit IL-17 induction of cytokines in
epithelial cells and fibroblasts [10]. We have also shown before that corticosteroids inhibit IL-
17A-induced IL-8 production of epithelial cells [33].
Regarding the effect of IL-17 levels on the lung function we found a negative correlation
between FEV1% predicted and IL-17 levels in the atopic individuals who did not use ICS. In
line with our finding, Irvin et al found a negative correlation between FEV1% and IL-17 levels
in their asthmatic population [20]. Reduced airway patency due to IL-17 mediated airway
inflammation may be responsible for this negative association, but also direct sensitization of
airway smooth muscle may play a role, as has been suggested in mouse with house-dust mite-
induced allergy [34]. Such a direct role of IL-17 in smooth muscle cell contraction is in accor-
dance with findings of a clinical trial demonstrating clinically meaningful effects of anti–IL-
17A, especially in a group with high reversibility of FEV1 in response to albuterol [35]. How-
ever, our study seems to contradict these results as we found an inverse relationship between
IL-17 expression and reversibility of FEV1 to albuterol. A direct comparison between the two
studies is unfortunately not possible, as Busse et al didn't measure expression of IL-17 levels in
their studied population [35]. Clearly, more research is necessary to understand the “high IL-
17 phenotype” of asthma and its consequences for personalized medicine.
In our study, IL-17 levels was significantly correlated with neutrophilic inflammation but
smoking did not contribute to the expression of IL-17. This supports the previous finding by
Doe et al where IL-17A and IL-17F expression in the submucosa of the lung tissue was not
associated with smoking status in their asthmatics [9]. However, our finding contrasts with a
study in healthy smokers and COPD patients, showing that smokers have more IL-17 express-
ing cells in the submucosa than nonsmokers [36]. We conclude that atopy and ICS use may
associate with a lower expression of IL-17 and that there are contradictory findings regarding
the contribution of smoking. One of the limitations of our study is that the scarce biopsy mate-
rial did not allow further investigating a potential explanation for the effect of ICS on IL-17+
cells. A very recent study shows that IL-17A/IL-4 dual producing cells are important in asthma
and may provide a potential explanation for ICS use decreasing IL-17A+ cells [20]. Future stud-
ies on human biopsy staining are warranted.
Conclusion
In summary, we here show that the IL-17+ cells present in airway wall biopsies of asthmatics
are mostly neutrophils and to a smaller extent eosinophils, and not, as the general paradigm
assumes lymphocytes (Th17). This is of interest since nonatopic asthmatics who do not use
inhaled corticosteroids have higher IL-17 expression in bronchial biopsies than atopic asth-
matics, suggesting a potential role of IL-17 in the pathogenesis of nonatopic asthma. ICS use
was associated with lower numbers of IL-17+ cells in both atopic and nonatopic asthmatics,
suggesting a beneficial effect of ICS in general.
Supporting Information
S1 Fig. Negative correlation, in non-inhaled corticosteroid (ICS) users, between the num-
ber of IL-17+ cells in the submucosa of bronchial biopsies and reversibility (%Predicted) in
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atopic and nonatopic asthmatics (rs = -0.33; p = 0.01) (A), and with FEV1% predicted in
atopic asthmatics (rs = -0.39; p = 0.01)(B). Solid circles are nonatopic asthmatics, and open
circles are atopic asthmatics.
(TIF)
S2 Fig. The number of IL-17+ cells in submucosa in bronchial biopsies from smoking and
nonsmoking asthmatics, who are inhaled corticosteroid (ICS) users or non-ICS users. Solid
circles are non-ICS users, and open circles are ICS users.
(TIF)
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